Abridge Review Australia 2026: A Strong US Scribe With No Australian Door

Verdict (TL;DR): Abridge is one of the most credible AI medical scribes in the world — deeply embedded in US health systems, built into Epic, and backed by serious money. For Australian clinicians, though, it is effectively unbuyable. There is no self-serve sign-up, no AU pricing, no published Australian data residency, and the whole model is built around US enterprise health systems running Epic. A GP in Hobart or a clinic in Geelong cannot simply pick this up. On product merit it is strong. On Australian fit it fails the gate. Australian clinicians should look at AU-built scribes instead.

Score: 14/25 — ⭐⭐⭐ Good

Australian Fit: 1/5 — no AU purchase path, no published AU data residency, US enterprise/Epic-only model.

Last reviewed: 7 June 2026 by Adam.

What Abridge is

Abridge is an ambient AI medical scribe. It listens to a clinician-patient conversation, then drafts a structured clinical note — and pushes it into the electronic health record (EHR). The aim is simple: cut the documentation load that drives clinician burnout.

It was founded in 2018 in Pittsburgh by Dr Shiv Rao, who remains CEO. The company grew out of the Pittsburgh Health Data Alliance, tied to the University of Pittsburgh, UPMC and Carnegie Mellon.

This is not a small startup. Abridge has raised heavily, capped by a US$300M Series E led by Andreessen Horowitz, with Khosla Ventures joining. The company says its platform supports over 50 million medical conversations a year, across 55 specialties and 28 languages, and is deployed at more than 150 US health systems.

Its marquee distinction: Abridge is Epic's first "Pal" partner, with native integration into Epic's clinician workflows. Its customer roster reads like a US hospital league table — Mayo Clinic, Kaiser Permanente, Johns Hopkins, Duke Health, Emory, UPMC.

In plain terms: this is enterprise-grade kit, sold to large American hospital systems, and it is good at what it does.

What it costs in Australia

Nothing — because you cannot buy it here.

Abridge publishes no pricing. It sells through negotiated enterprise contracts to health systems. There is no self-serve sign-up, no per-seat checkout, and no public price list. Individual clinicians, solo GPs and small practices cannot purchase it directly.

• Per clinician, per year: Abridge sells via enterprise contract only and publishes no public price. Some third-party write-ups quote per-clinician figures, but Abridge confirms none of them, so we don't report a number.
• Currency: US dollars. There is no AUD pricing.
• GST: There is no AU purchase path, so the question is hypothetical. As general guidance, an overseas supplier of services to an Australian business would typically fall under Australia's imported-services GST rules — but that is a tax-position matter for your accountant, not a vendor-stated figure.

The honest position: for an Australian reader, the cost question is moot. The product is not sold into this market in any accessible form.

How it works in practice

The workflow, as Abridge describes it for its US customers, is tight:

1. The clinician starts a session on a phone or desktop app during the consult.
2. Abridge captures the conversation and drafts a structured, billable note in real time.
3. For Epic sites, the note flows directly into the right chart sections via native integration.

Abridge also lists integrations with athenahealth, Oracle Health (Cerner), eClinicalWorks, Allscripts and NextGen. The Epic experience is the deepest by design.

Here is the problem for Australia. The EHR landscape here looks nothing like the US. Australian general practice runs on Best Practice and MedicalDirector. Hospitals run a mix that includes Epic at some large sites, but also Cerner, and state-based systems. Abridge's whole value lever — native Epic embedding — does not map onto the software most Australian clinicians actually use.

What it does well

• Deep EHR integration. As Epic's first Pal partner, notes land in the chart automatically rather than via copy-paste. For Epic sites, that is genuinely strong.
• Enterprise-grade security posture. Abridge holds SOC 2 Type 1 and Type 2, is HIPAA-aligned, and lists CCPA and TX-RAMP.
• Proven scale. 150+ US health systems and 50M+ conversations a year is real-world validation, not a pilot.
• Multilingual and multi-specialty. 28 languages and 55 specialties is broad coverage for varied clinical settings.
• Serious backing. US$300M Series E from a16z signals staying power — this vendor is not going away.

What it doesn't do well

• No Australian purchase path. There is no way for an AU clinician or practice to buy this. Enterprise-only, US-focused.
• No published Australian data residency. Abridge's trust centre lists no data hosting location and no AU region. For health data under the Privacy Act and APP 8, that silence is disqualifying for AU use until clarified.
• US-only compliance frame. HIPAA, CCPA and TX-RAMP are US regimes. There is no stated Australian Privacy Act posture and no mention of My Health Record alignment.
• EHR mismatch. Its core advantage is Epic embedding. Most Australian general practice runs Best Practice or MedicalDirector, where Abridge offers no integration.
• No public pricing. You cannot assess value because there is no published price; Abridge sells by enterprise contract only.

Australian fit

This is where Abridge comes apart for our readers, and we will not soften it.

Data residency. Abridge does not publish where patient data is stored. Its trust centre names US frameworks and US infrastructure vendors, with no Australian region and no residency statement. Under the Privacy Act 1988 and APP 8 (cross-border disclosure), an Australian practice handling sensitive health information needs to know exactly where that data goes and under whose law it sits. Abridge does not answer that question for the Australian market.

Privacy and regulatory posture. The compliance set is HIPAA, SOC 2, CCPA and TX-RAMP — all US. There is no stated Australian Privacy Act alignment, no My Health Record consideration, and nothing addressed to AHPRA, RACGP or MBS documentation requirements.

Availability. No AU sales motion, no AU pricing, no AU support presence is published. The model is US enterprise health systems.

EHR fit. The Epic-first design does not match the Best Practice / MedicalDirector reality of Australian general practice.

Currency. USD-only, no AUD.

A note that applies to every scribe, Abridge included: an AI scribe does not replace clinical judgement. The treating clinician remains responsible for the accuracy of the medical record and must review every generated note before it is signed.

Australian Fit score: 1/5.

Alternatives

For Australian clinicians, locally built tools win decisively on the criterion that matters most here — local fit.

• Heidi Health — Melbourne-built, AU data residency options, broad EHR support across AU practice software. Built for this market from the start.
• Lyrebird Health — Australian-founded scribe, designed around AU general practice workflows and AU EHRs.
• Microsoft Dragon Copilot — global enterprise scribe with a clearer multi-region story than Abridge, worth a look for larger AU hospital settings, though still verify AU data residency directly.

The AU-built options (Heidi, Lyrebird) score better on Australian Fit because they answer the residency, EHR and support questions that Abridge leaves blank. We will review each in this category.

Bottom line

Abridge is a genuinely strong product. If you are a US clinician at an Epic health system, it is among the best ambient scribes available. None of that translates to Australia. You cannot buy it as an AU practice, you cannot confirm where the data lives, and its Epic-first design misses the software most Australian clinicians use. It is a Very Good product losing badly on local fit. For Australian clinicians today, look to Heidi or Lyrebird instead. Revisit Abridge only if it announces an Australian data-residency option and an AU go-to-market.

Score

Total: 14/25 — ⭐⭐⭐ Good

Australian Fit gate: 1/5 — Australian Fit is below 4/5, so Abridge cannot be rated Excellent and cannot be a category Top Pick, regardless of raw score. See our Methodology.

Frequently asked questions

Is Abridge available in Australia?

Not in any accessible form. There's no self-serve sign-up, no AU pricing, and no AU support presence. Abridge sells through negotiated enterprise contracts to US health systems. A solo GP or small practice cannot buy it directly here.

Does Abridge charge in AUD?

No. Pricing is USD only and not even published — Abridge sells by enterprise contract with no public price list. Because there's no AU purchase path, the GST question is hypothetical and a matter for your accountant.

Where does Abridge store patient data?

Abridge publishes no data-residency statement and names no Australian region. For health data under the Privacy Act 1988 and APP 8, that silence is disqualifying for Australian use until clarified.

What should Australian clinicians use instead?

Locally built scribes win on the criterion that matters most here. Heidi Health (Melbourne-built, AU residency options) and Lyrebird Health (Australian-founded, designed around AU general practice) answer the residency, EHR and support questions Abridge leaves blank.

Read next

• Category guide: Best AI Medical Scribes in Australia 2026

Sources

1. Abridge — homepage ("Enterprise-grade AI for clinical conversations") — https://www.abridge.com/ — Wayback: https://web.archive.org/web/20260604105543/https://www.abridge.com/ — checked 7 June 2026
2. Abridge — Series E announcement (US$300M, a16z lead, 150+ health systems, 50M+ conversations, 55 specialties, 28 languages) — https://www.abridge.com/blog/series-e — Wayback: http://web.archive.org/web/20260607131601/https://www.abridge.com/blog/series-e — checked 7 June 2026
3. Abridge — Series C press release (Pittsburgh HQ, founded 2018, Dr Shiv Rao CEO, US$150M Feb 2024) — https://www.abridge.com/press-release/series-c-150 — Wayback: https://web.archive.org/web/20260307143031/https://www.abridge.com/press-release/series-c-150 (snapshot 7 Mar 2026) — checked 7 June 2026
4. Abridge — Trust Center (SOC 2 Type 1 & 2, HIPAA, CCPA, TX-RAMP, WCAG 2.2 AA; no data residency detail) — https://trust.abridge.com/ — Wayback: https://web.archive.org/web/20260323193907/https://trust.abridge.com/ (snapshot 23 Mar 2026) — checked 7 June 2026
5. Abridge — "Abridge Becomes Epic's First Pal" press release (Epic native integration) — https://www.abridge.com/press-release/abridge-becomes-epics-first-pal-bringing-generative-ai-to-more-providers-and-patients — Wayback: https://web.archive.org/web/20251217004240/https://www.abridge.com/press-release/abridge-becomes-epics-first-pal-bringing-generative-ai-to-more-providers-and-patients (snapshot 17 Dec 2025) — checked 7 June 2026
6. Abridge — Customers page (Mayo, Kaiser, Johns Hopkins, Duke, Emory, UPMC) — https://www.abridge.com/customers — Wayback: https://web.archive.org/web/20260510123923/https://www.abridge.com/customers — checked 7 June 2026

The AI Directory Australia is an independent editorial publication. We don't accept payment for positive reviews. Read our Methodology and Affiliate Disclosure.